GNRH1 and metastatic prostate carcinoma: Hormone therapy, either by surgery or drug therapy (eg, gonadotropin‐releasing hormone [GnRH] agonists or antagonists), is the most common treatment for localized, advanced, and metastatic prostate cancer.5, 6 Both GnRH agonists, such as leuprorelin acetate and goserelin acetate,7, 8 and the GnRH antagonist, degarelix,9 are approved in Japan.